BioCentury
ARTICLE | Company News

Intellipharmaceutics, AstraZeneca neurology, drug delivery news

August 6, 2012 7:00 AM UTC

AstraZeneca granted Intellipharmaceutics rights to market generic versions of the 50, 150, 200, 300 and 400 mg strengths of AstraZeneca's antipsychotic Seroquel XR quetiapine fumarate in the U.S. on Nov. 1, 2016, or earlier under undisclosed circumstances. The deal is part of a settlement resolving a suit filed in April by AstraZeneca in the U.S. District Court for the Southern District of New York alleging that Intellipharmaceutics' ANDA for a generic version of Seroquel XR infringes AstraZeneca's U.S. Patent No. 5,948,437. The patent, which covers the sustained-release formulation of quetiapine fumarate, expires in May 2017, with pediatric exclusivity expiring in November 2017. Intellipharmaceutics' ANDA included a paragraph IV certification claiming that the '437 patent is invalid and unenforceable. ...